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Background: Knowledge about tumour gene mutation status is essential for the treatment of increasing numbers
of cancer patients, and testing quality has a major impact on treatment response and cost. In 2012, 4,629 tests for
BRAF p.V600 were performed in France, in patients with melanomas.
Methods: Two batches of unstained melanoma sections were sent, in May and November 2012, to the 46
laboratories supported by the French National Institute of Cancer (INCa). An external quality assessment (EQA)
evaluated mutation status, response times and compliance with INCa recommendations.
Results: All the French laboratories involved in testing participated in the EQA. Fourteen different methods were
used to detect BRAF mutations, most consisting of combinations of in-house techniques. False responses were
noted in 25/520 cases (4.8%), 11 of which concerned confusion between p.V600E and p.V600K. Thus, 2.7% of
responses would have led to inappropriate treatment. Within six months, mean response times decreased from 22
to 12 days (P<0.001), and the percentage of samples evaluated by a pathologist for tumour cell content increased,
from 75.2% to 96.9% (P<0.001).
Conclusion: Despite the use of non-certified methods, the false response rate was low. Nationwide EQA can
improve the quality of molecular pathology tests on tumours.Background
Molecular pathology tests on tumours are increasingly
required by clinicians seeking targeted treatments for pa-
tients with cancers. The list of targeted therapies is rapidly
expanding, and molecular tests are already mandatory to
guide treatment decisions for patients with metastatic colo-
rectal carcinomas with EGFR antibodies [1,2], lung carcin-
omas with EGFR inhibitors [3] and metastatic melanomas
with BRAF inhibitors [4]. These tests are usually performed
on DNA extracted from formalin-fixed paraffin-embedded
(FFPE) tumour samples. In 2005, trastuzumab was shown
to improve the survival of patients with breast carcinomas
[5,6], and the evaluation of HER2 status became mandatory* Correspondence: jean-francois.emile@uvsq.fr
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reproduction in any medium, provided the orin patients with such tumours. However, in 2006, central
testing for 2535 patients confirmed only 86% of the results
obtained in local laboratories [7], and there was still some
debate about the reliability of testing for HER2 amplifi-
cation in 2011 [8]. Thus, since 2005, thousands of pa-
tients may have received inappropriate treatment due to
false results in mutation tests. The history of in situ test-
ing for HER2 should encourage physicians and health
authorities to pay attention to the quality of mutation
testing in cancers.
Disease-free and overall survival is improved by treatment
with the specific inhibitor vermurafenib, in patients with
advanced or metastatic melanomas with BRAF mutations
[4,9]. This has led US and European authorities to approve
its use for patients with p.V600E or p.V600 mutations,
respectively. Clinical benefit has also been demonstrated
for other BRAF and/or MEK inhibitors [10,11], and clinicaltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease. Thus, since June 2011the determination of BRAF
mutational status has been obligatory, to determine the best
treatment options for patients with late-stage melanomas.
In 2008, the French National Institute for Cancer (INCa)
initiated a nationwide program for the development of re-
gional platforms for molecular pathology testing for cancers
[12]. This national network consists of 28 platforms involv-
ing 46 laboratories. These laboratories are supported by
grants from INCa, and all the tests are performed free
of charge. In 2011, 20,761 EGFR tests for lung non-small
cell carcinomas and 17,153 KRAS tests for colorectal
carcinomas (http://www.e-cancer.fr) were performed. In
practical terms, any of the 63,703,191 inhabitants of France
(http://www.insee.fr) can benefit from molecular pathology
analysis for free, provided it is necessary for treatment, and
this nationwide program can thus be considered a success.
The French platforms performed 3,479 BRAF tests on
melanoma samples in 2011 and 4,629 in 2012.
This study is the first evaluating the quality of the
tests performed in this national network. We used three
parameters to assess quality: BRAF mutation status, re-
sponse times and conformity to the French recommen-
dations for test reporting.
Methods
The EQA involved two independent tests, performed in
May and November 2012. The protocol was identical
for both tests (May and November): 10 formalin-fixed
paraffin-embedded (FFPE) samples with massive lymph
node metastases were obtained from the Ambroise Paré
Centre for Biological Resources (Boulogne, France). The
study was approved by the Ile de France 8 institutional
review board (#12 01 08). The samples studied were
taken from patients who had already died before the
start of the study. Four patients had a p.V600E, one had
a p.V600K and five had no BRAF p.V600 mutations.
The reference mutational status was checked by Cobas
[4] and pyrosequencing [13,14]. A dedicated computer
program was developed (Lincoln, Boulogne, France) to
anonymise each sample and each participating laboratory
through the assignment of random code numbers. Each
sample received three different identification numbers, to
prevent the exchange of information between participating
laboratories. For each test, six of the ten samples were
selected at random, such that the final set of six samples
contained at least two cases with and two cases without
BRAF mutations. The participating laboratories, EQA or-
ganisers and sponsor were unaware of the samples chosen
until the databases of collected responses were blocked.
Each of the ten selected FFPE samples was re-embedded
in two twin blocks, and the six selected cases were then
re-embedded again by an external pathology laboratory
(IPP, Paris, France) for anonymisation. Serial 4 μm-thicksections were cut from the same FFPE block where pos-
sible, or from the twin block if the first block had already
been used up. Sections were cut in a dedicated molecular
pathology environment (specific room, equipment, reagents
and trained technicians). Slides were received by the
participating laboratories within four weeks of cutting.
The participating laboratories were aware of the month,
but not of the day of testing.
Participation in this external quality control (EQA) study
was free of charge. The protocol was sent to all the French
laboratories and to four other European laboratories. All
the laboratories contacted agreed to participate (n=50). The
results of the first test (May) were communicated to the
laboratories (in July) before the second test was carried out
(November). The French recommendations were available
from the INCa web site (http://www.e-cancer.fr). Minor
modifications to these recommendations were published
between tests #1 and #2, and all the laboratories were
informed of these changes.
All original molecular pathology reports were sent by
post, fax and/or e-mail to Lincoln, for anonymisation.
Anonymised reports were analysed by the organising la-
boratory and data the data were entered into the dedicated
software. BRAF mutation status was entered twice, inde-
pendently. Compliance with French recommendations was
evaluated by analysing each original report and scoring 15
different parameters 0, 1, 2 or 3, corresponding to “absent”,
“incomplete” and “complete”, respectively; Additional file 1:
Table S1). Response time was determined as the interval
between the day of delivery of the slide batches by the
transporter and the day on which the corresponding report
was received. The maximum acceptable response time was
40 days in test #1 and 28 days in test #2. A “good” response
was defined as indicated in Table 1. This EQA did not
evaluate the methods used by the various laboratories to
assess BRAF status, but the collection of this information
was optional.
The quality of the DNA obtained from the FFPE samples
was assessed after the completion of both tests. DNA
was quantified by spectrophotometry (Nanodrop) and
concentrations were adjusted to 25 ng/μl. Real-time PCR,
generating an 80-base pair amplicon [15], was performed
14 times on each sample.
For the six samples of test #2, a deep sequencing analysis
was performed, with the Ion AmpliSeq™ Cancer Hotspot
Panel v2 primer pool and Ion AmpliSeq ™ Master Mix v2.0
(Ion Torrent, Life Technologies, Carlsbad, CA), according
to the protocol recommended by the manufacturer.
The multiplexed amplicon library concentration and
size was determined with an Experion™ DNA analysis
kit (Bio-Rad Laboratories Inc., Hercules, CA). Samples
were barcoded with the Ion Xpress Barcode Adapters
1–16 Kit, according to the manufacturer’s instructions
(Ion Torrent, Life Technologies) and multiplexed for
Table 1 Evaluation of the quality of responses for BRAF
p.V600 mutational status
BRAF status Response of the tested
laboratory
Evaluation
No p.V600 mutation Absence of p.V600 mutation Correct result
No p.V600 mutation Presence of p.V600, p.V600E
or p.V600K
Incorrect result
p.V600E Presence of p.V600 or p.V600E Correct result
p.V600E Presence of p.V600K Incorrect result
p.V600K Presence of p.V600 or p.V600K Correct result
p.V600K Presence of p.V600E Incorrect result
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316 Chip, on a Personal Genome Machine Sequencer
(PGM, Ion Torrent, Life Technologies). The variants were
characterised with the associated variant caller software.
Statistical analysis was performed with SAS software
(SAS Institute, Cary, USA). Chi-squared or Fisher’s exact
tests were used to assess differences for qualitative data,
and analysis of variance or non-parametric Mann–Whitney
tests were used to assess differences for quantitative data.
All tests were two-tailed and a significance threshold of 5%
was applied in all cases.
Results
The 12 samples randomly selected for the tests
corresponded to four cases with c.1799T>A, p.V600E,
two cases with c.1798_1799GT>AA, p.V600K, and six
cases without p.V600 BRAF mutations. The four European
laboratories responded in due time in all cases and were
evaluated only for BRAF status. The results were correct
for 47/48, and false for one case (no mutation for a sample
with a p.V600K mutation).
The following results concern only the 46 French labora-
tories, one of which participated only in the second test.
We received 524 of the 546 responses expected within an
acceptable timeframe (40 days for test #1, and 28 days for
test #2). A technical failure of the determination of BRAF
status was reported in four of these responses. Thus,
overall, BRAF status was evaluated in an acceptable
timeframe in 520 of 546 (95.2%) samples.
BRAF mutation status
Correct results were obtained in 495 of these 520 responses
(95.2%, 95% confidence interval [93.4-97.0]). Eleven of
the false results were for p.V600, with confusion between
p.V600E and p.V600K. This would have had no impact
on treatment in Europe, where vemurafenib treatment
is authorised for any p.V600 BRAF mutation. Fourteen of
the 520 (2.7%, 95% confidence interval [1.3–4.1]) patients
would have received incorrect results with a potential im-
pact on treatment strategy. No false results were obtained
for 25 of the 46 laboratories (one of which analysed onlythe six samples for the second test), 17 laboratories gave
one false result, and four gave two false responses for the
12 samples tested. The correct result rate appeared to im-
prove slightly between the first (249/263; 94.7%) and second
(247/258; 95.7%) tests, but this different was not significant.
We matched the BRAF results with the position of the
serial tissue sections, to check for possible tumour het-
erogeneity (Additional file 2: Figure S1). All sections for
which false results were obtained were surrounded by
sections for which good results were obtained, and the
maximum thickness of tumours giving false results was
36 μm (3 batches of 3 slides, each 4 μm thick).
For the samples of test #2, one laboratory reported a
minor (5%) c.1799T>A, p.V600E mutation in a wild-type
sample, and additional BRAF c.1793C>T, p.Ala598Val,
BRAF c.1807C>T, p.Arg603* mutations were reported by
other laboratories. We checked these data by subjecting
tumour DNA from the six samples to deep sequencing. The
lowest sequence depth for the BRAF c.1793C to c.1807C re-
gion was 214 for the six samples (range [214 to 2246]), and
the original mutational status of each sample was confirmed,
excluding the possibility of additional and low-frequency
mutations. All p.V600E mutations were also confirmed by
immunohistochemistry with the VE1 antibody (not shown).
Detection methods
Five laboratories changed their methods for BRAF p.V600
mutation detection between the two tests. Only one of
these laboratories had had a false result in the first test.
Fourteen different strategies were used, corresponding
to combinations of one (52%), two (40%) or three (8%)
of the following techniques: Sanger sequencing (37.9%),
pyrosequencing (18.3%), high-resolution melting (HRM;
17.5%), allele-specific real-time PCR (15.3%), SNAPshot
(9.5%) and Cobas (1.5%). All but one of these strategies
included at least one technique developed in the labora-
tory concerned. None of the techniques used was asso-
ciated with a significantly higher rate of false results
(P=0.8; Additional file 1: Table S2).
Correlation of false results with samples
The proportion of false results depended on the samples
analysed and ranged from 0/44 (0%) for seven samples
(3 with p.V600E and 4 with no mutation) to 12/44
(27.3%; Figure 1). The frequency of false results was
highest for the two samples with p.V600K mutations
(24.1% vs. 0.9%, P<0.001, Fisher’s exact test). We assessed
the quality of the DNA obtained from FFPE samples,
by comparing the number of DNA copies amplified by
real-time PCR from each sample, at a given concentra-
tion of DNA. The mean CT values for the amplified
DNA copies of the 12 samples were significantly different
(P<0.0001, analysis of variance), ranging from 27.4 to 31.2.
All but one of the false responses occurred in the six cases
Figure 1 BRAF p.V600 status responses obtained from the 46 French laboratories. Among the 12 samples tested, two had more than 20%,
and three others had only a few (<5%) false responses.
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indicating low DNA quality.
Response times - compliance with French
recommendations
Response times (Figure 2) improved between tests #1
and #2, from a mean of 22 to 12 days (P<0.001, Mann–
Whitney test).
Compliance with French INCa recommendations was
evaluated by calculating an overall score. The mean
scores obtained were 33.2 and 33.5 for tests #1 and #2,
respectively (maximum possible score = 40). No evaluation
of the percentage of tumor cells was available for 60/263Figure 2 Response time. Response time, corresponding to the
number of days between delivery by the transporter and reception
of the report by the correspondent significantly improved (P<0.001)
over the six-month period between the two tests (tests #1 and #2
were performed in May and November 2012, respectively).(22.8%) and 8/260 (3.1%) of the samples in tests #1 and #2,
respectively (P<0.001, Fisher’s test).
Discussion
The health authorities of France (a country with 62 million
inhabitants) have set up a network for the detection of
somatic mutations in cancers, including BRAF p.V600
mutations in melanomas. This network carried out 3,479
tests for BRAF mutations in 2011 and 4,629 such tests in
2012. This study, the first EQA for this testing, revealed
that only 2.7% of the results were false and had potential
clinical implications, despite the use of techniques de-
veloped in the laboratory concerned and not certified,
by most of the 46 laboratories. Most of the false results
obtained related to two samples with a p.V600K muta-
tion and poor DNA quality. Response time and patho-
logical evaluations of samples improved significantly in
the six months between the tests, as did the evaluation
of tumour cell content.
The response time for tests of BRAF status is a major
issue. Indeed, the median overall survival of patients with
stage IV or advanced melanomas not treated with BRAF
inhibitors is only six to 10 months [9]. Thus, treatment
strategies, such as targeted or immune therapies, and/or
possible inclusion in a clinical trial must be considered
within the first month after diagnosis. This target in terms
of timing is currently met by expert centres, but remains
difficult to achieve in a nationwide network. The mean
response time for test #1 was 22 days. This came as
something of a surprise, because the expected response
time was nine days, based on the data provided by each
laboratory to INCa in 2011 (http://www.e-cancer.fr). The
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the maximum response time from 40 to 28 days for test #2.
In test #2, the mean response time was significant bet-
ter, falling from 22 to 12 days (P<0.001). We attribute
this important progress to the EQA and the discussion
of the results obtained with all laboratories between
tests #1 and #2. However, our findings cannot be considered
to demonstrate a similar improvement of response times
in routine practice. Quality management at all French
medical laboratories, according to ISO 15189, and cer-
tification within the seven next years should also help
to decrease response times.
This study revealed that almost all French laboratories
are currently using tests developed in-house. Cost may
be one of the chief reasons for this. Indeed, the use of a
certified test to assess the BRAF status of tumour DNA
costs at least twice as much as the use of in-house tech-
niques [16]. However, the widespread use of non-certified
detection methods might generate a high rate of false re-
sults. We show here that the false result rate was only 2.7%,
only one third that for the pathological diagnosis of rare
tumours in France (http://www.e-cancer.fr). Interestingly,
the false result rate was not found to be related to the type
of technique used, although the small number of samples
(n=12) and the wide range of combinations of techniques
used (n=17) limits our interpretation of this finding.
Twelve samples were tested, and 54%, 37% and 9% of
the participating laboratories had no, one and two false
results, respectively. Training at each laboratory is prob-
ably of considerable importance for limiting false results.
Unfortunately, as the results were rendered anonymous
for the EQA, we were unable to compare false result
rates between laboratories as a function of their level of
activity. The false result rate depended strongly on the
sample and ranged from 0% to 27.3%. We therefore tried
to identify parameters associated with a high false result
rate. We found that the type of p.V600 mutation and the
quality of the DNA obtained from the sample were sig-
nificantly associated with the likelihood of false results.
The false results rate was highest for the two cases with
p.V600K mutations. These findings are consistent with
those reported for another series, in which 30% of
pV600K mutations were not detected by real-time PCR
[17]. Real-time PCR with 25 ng/μl DNA revealed signifi-
cant differences in the quality of the DNA obtained from
the 12 samples (P<0.0001), with CT values from 27.4 to
31.2. The tissue must be fixed and embedded in paraffin
for diagnosis in clinical practice, but these procedures
may modify the nucleic acid [18]. Interestingly, false result
rates of 1/260 and 24/261 were obtained for the six samples
with the highest DNA quality and the six samples with the
lowest DNA quality, respectively. There were too few sam-
ples to determine whether the type of p.V600 mutation and
DNA quality had independent effects on the risk of a falseresult. However, our data suggest that the staff of these la-
boratories should be trained in the detection of rare p.V600
mutations, and consider routine testing the quality of DNA
obtained from FFPE samples.
Conclusions
In conclusion, we show here, for the first time, that na-
tionwide EQA can improve the quality of molecular
tests on FFPE tumour samples. We also show that, des-
pite the use of several combinations of in-house tests,
the false result rate for BRAF testing in melanoma was
low. Finally, our data suggest that the training of la-
boratory staff to detect rare mutations and assessments
of DNA quality might limit the risk of false results.
Additional files
Additional file 1: Table S1. Evaluation of compliance with French
recommendations. Table S2: False responses, by technique used 48% of
the laboratories used a combination of two or three techniques to
evaluate BRAF status. Table S3: BRAF p.V600 status and DNA quality of
the FFPE melanoma samples.
Additional file 2: Figure S1. BRAF p.V600 status results for serial tissue
sections of the FFPE samples. In two cases (#08.12.20 and # 02.04.16)
more than two false responses were obtained. Each false result was
obtained for sections surrounded by sections that gave correct results,
excluding the possibility of tumour heterogeneity.
Abbreviations
INCa: French National Institute for Cancer; EQA: External quality assessment;
EGFR: Epidermal growth factor receptor; DNA: Eeoxyribonucleic acid;
FFPE: Formalin-fixed paraffin-embedded; ISO: International Organisation for
Standardisation.
Competing interests
JFE, AL, PH, JCS and PLP received honoraria from Roche for expert advice on
diagnosis and/or for studies on patients with melanomas. JFE received
honoraria from Glaxo Smith Kline for expert advice on the diagnosis and/or
treatment with BRAF inhibitors of patients with cancers. LB is employed by
Roche.
Authors’ contributions
JFE, JT and and LB designed the study, collected the data, contributed to
data interpretation, wrote the manuscript. FN, SS, GF, AL, DL, ZHR, PH, JCS
and PLP provided data, contributed to data interpretation. All authors read
and approved the final manuscript. Members of the BRAF EQA Group
provided data and contributed to data interpretation.
Acknowledgement
BRAF EQA Group: Drs Cécile Aube (Clermont-Ferrand, France), Lebkir Baala
(Orléans, France), Jean Ben Hattar (Lausanne, Switzerland), Christophe Boyer
(Nîmes, France), Frédéric Charlotte (Paris, France), Pascale Cervera (Paris,
France), Eric Clauser (Paris, France), Florence De Fraipont (Grenoble, France),
Pierre Dechelotte (Clermont-Ferrand, France), Chantal Delvincourt (Reims,
France), Marc Denis (Nantes, France), Laurent Doucet (Brest, France), Karine
Durand (Limoges, France), Fabienne Escande (Lille, France), Carole Ferraro-
Peyret (Lyon, France), Françoise Galateau-Salle (Caen, France), Cécile Haratyk
(Dijon, France), Rémy Heller (Colmar, France), Philippe Jonveaux (Nancy,
France), Lucie Karayan-Tapon (Poitiers, France), Roger Lacave (Paris, France),
Ludovic Lacroix (Villejuif, France), Laurence Lamant (Toulouse, France),
Jérôme Lamoril (Paris, France), Jean Lamy (Montpellier, France), Antoinette
Lemoine (Villejuif, France), Karen Leroy (Créteil, France), Sarab Lizard (Dijon,
France), Fernando Lopez-Rios (Madrid, Spain), Sabine Merkelbach-Bruse
(Cologne, Germany), Jean-Louis Merlin (Nancy, France), Jean-Philippe Merlio
(Bordeaux, France), Samia Mourah (Paris, France), Isabelle Nanni Metellus
Emile et al. BMC Cancer 2013, 13:472 Page 6 of 6
http://www.biomedcentral.com/1471-2407/13/472(Marseille, France), Jean Pages (Tours, France), Florence Pedeutour (Nice, France),
Michel Peoc’h (Saint-Etienne, France), Jean-Luc Pretet (Besançon, France),
Delphine Prunier (Angers, France), Nathalie Rioux-Leclercq (Rennes, France),
Etienne Rouleau (Saint-Cloud, France), Hagay Sobol (Marseille, France), Jérôme
Solassol (Montpellier, France), Stéphanie Trudel (Amiens, France), Sabine Vande
Borght (Leuven, Belgium), Qing Wang (Lyon, France).
Financial support
This work was funded by Roche France.
Author details
1EA4340, Versailles SQY University, Boulogne, France. 2Department of
Pathology, Ambroise Pare Hospital, APHP, 9 Av. Charles de Gaulle, Boulogne
F-92104, France. 3Roche, Boulogne, France. 4Institut National du Cancer
(INCa), Boulogne, France. 5CHU de Rouen, Rouen, France. 6UMR775, INSERM
and Université Paris-Descartes, Paris, France. 7Laboratory of Clinical and
Experimental Pathology, Pasteur Hospital and Medical School, Nice Sophia
University, Nice 06002, France.
Received: 27 June 2013 Accepted: 1 October 2013
Published: 11 October 2013
References
1. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S,
Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A,
Celik I, Rougier P, Ciardiello F: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal cancer:
updated analysis of overall survival according to tumor KRAS and BRAF
mutation status. J Clin Oncol 2011, 29(15):2011–2019.
2. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché
O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M,
Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P: KRAS mutations as an
independent prognostic factor in patients with advanced colorectal
cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374–379.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H,
Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H,
Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y,
Hagiwara K, Morita S, Nukiwa T: North-East Japan Study Group. Gefitinib
or chemotherapy for non-small-cell lung cancer with mutated EGFR.
N Engl J Med 2010, 362(25):2380–2388.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R,
Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf
D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop
K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group:
Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med 2011, 364(26):2507–2516.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M,
Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M,
Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I,
Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex
V, Ward C, Straehle C, McFadden E, et al: Herceptin Adjuvant (HERA) Trial
Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer. N Engl J Med 2005, 353(16):1659–72.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE,
Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM,
Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB,
Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark
N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive
breast cancer. N Engl J Med 2005, 353(16):1673–84.
7. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ,
Ingle JN, Visscher D, Jenkins RB: HER2 testing by local, central, and reference
laboratories in specimens from the North Central Cancer Treatment Group
N9831 intergroup adjuvant trial. J Clin Oncol 2006, 24(19):3032–8.
8. Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown
AM: Determining true HER2 gene status in breast cancers with polysomy
by using alternative chromosome 17 reference genes: implications for
anti-HER2 targeted therapy. J Clin Oncol 2011, 29(31):4168–74.
9. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur
GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D,
Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye
F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A: Survival in BRAF V600-mutantadvanced melanoma treated with vemurafenib. N Engl J Med 2012,
366(8):707–14.
10. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M,
Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska
B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert
ME, Goodman V, Chapman PB: Dabrafenib in BRAF-mutated metastatic
melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Lancet 2012, 380(9839):358–65.
11. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV,
Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J,
Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS,
Ouellet D, Martin AM, Patel K, Schadendorf D, METRIC Study Group:
Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med 2012, 367(2):107–14.
12. Nowak F, Soria JC, Calvo F: Tumour molecular profiling for deciding
therapy-the French initiative. Nat Rev Clin Oncol 2012, 9:479–86.
13. Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Hélias-Rodzewicz Z, Marin
C, Peschaud F, Chagnon S, Zimmermann U, Clerici T, Emile JF: Prognostic
value of BRAF(V600) mutations in melanoma patients after resection of
metastatic lymph nodes. Ann Surg Oncol 2012, 19(13):4314–21.
14. Colomba E, Hélias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N,
Pechaud D, Surel S, Côté JF, Peschaud F, Capper D, Blons H, Zimmermann U,
Clerici T, Saiag P, Emile JF: Detection of BRAF p.V600E mutations in
melanomas: comparison of four methods argues for sequential use of
immunohistochemistry and pyrosequencing. J Mol Diagn 2013, 15(1):94–100.
15. Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, Laurent-Puig P,
Blons H: Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR
mutation detection in clinical formalin-fixed paraffin-embedded
samples. Exp Mol Pathol 2012, 92(3):275–80.
16. Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F,
Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G,
Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F,
Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P: MOKAECM
collaborative group. Performance and cost efficiency of KRAS mutation
testing for metastatic colorectal cancer in routine diagnosis: the
MOKAECM study, a nationwide experience. PLoS One 2013, 8(7):e68945.
17. Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R,
Kovach B, Lee JR, Ochoa P, Langland R, Halait H, Lawrence HJ, Dugan MC:
Multisite analytic performance studies of a real-time polymerase chain
reaction assay for the detection of BRAF V600E mutations in formalin-
fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch
Pathol Lab Med 2012, 136(11):1385–91.
18. Do H, Wong SQ, Li J, Dobrovic A: Reducing sequence artifacts in
amplicon-based massively parallel sequencing of formalin-fixed paraffin-
embedded DNA by enzymatic depletion of uracil-containing templates.
Clin Chem 2013, 59(9):1376–83.
doi:10.1186/1471-2407-13-472
Cite this article as: Emile et al.: Improvement of the quality of BRAF
testing in melanomas with nationwide external quality assessment, for
the BRAF EQA group. BMC Cancer 2013 13:472.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
